Ribo Life Science (Suzhou Ribo Life Science Co., Ltd.) disclosed that it bought back 186,600 H shares on 13 July 2026 under its existing shareholder-approved mandate. The transaction totalled HK$9.30 million, implying an average purchase price of approximately HK$49.85 per share.

The buy-back was carried out on the open market and all repurchased shares will be held as treasury stock. The mandate authorising such repurchases was granted at the company’s annual general meeting on 5 June 2026.

Management stated that the operation reflects confidence in the group’s business outlook and is intended to enhance shareholder value. Future repurchases may be undertaken subject to market conditions and compliance with relevant regulations.

The board advised investors to exercise caution when dealing in the company’s securities, noting that the scale and timing of any further buy-backs remain at its discretion.